Introduction
Essential hypertension is known to be associated with the metabolic syndrome, which is characterized by insulin resistance, and strongly linked to the development of fatty liver (hepatic steatosis). Fatty liver is a common problem and there are a number of causes, including alcohol ingestion and hepatitis C infection (Table 1) . 1 Increasingly, patients are found to have fatty liver with no obvious cause. These patients often have non-alcoholic fatty liver disease (NAFLD), which has a prevalence of between 3 and 20% in Asian and Western populations. 2 Although patients with fatty liver and normal liver biochemistry have little risk of progressive liver disease, [3] [4] [5] [6] [7] there is increasing evidence that NAFLD is associated with a significant risk of progression to cirrhosis, 5, 8, 9 and may be responsible for up to 30% of end-stage liver disease. 10 The purpose of this review is to discuss the evidence for an association between essential hypertension and NAFLD, and to consider the diagnosis and management of NAFLD.
Hypertension, metabolic syndrome and fatty liver
Essential hypertension is known to be associated with the metabolic syndrome ( Table 2) ; 11 hyperinsulinaemia being seen in up to 50% of non-obese patients with hypertension. 12 Abdominal obesity, which is a major risk factor for the development of hypertension, 13, 14 is also associated with insulin resistance and the metabolic syndrome. 15 The presence of insulin resistance also seems to be involved in the pathogenesis of complications related to hypertension. 16, 17 An association between abnormal liver function tests and hypertension was identified by Ramsay in 1977, 18 who found that up to 15% of all male hypertensive patients had abnormal liver function tests. Over the past 20 years, several epidemiological studies have highlighted the particular association of raised g-glutamyl transferase (gGT) and hypertension. [19] [20] [21] [22] [23] [24] [25] A recent prospective study has confirmed a positive association between age, serum gGT and the subsequent risk of hypertension. 26 This relationship between gGT and hypertension may be independent of alcohol consumption, where gGT has been shown to correlate with systolic and diastolic blood pressure (Table 3) . 27 The reasons for these associations have been poorly understood; although alcohol consumption may be relevant, the causal link in many individuals between liver disease and hypertension seems to be the metabolic syndrome (Figure 1) .
Although hypertension has been associated with the development of severe NAFLD in obese patients, 28 hypertension and fatty liver have also been linked in the non-obese population. 29 Fatty liver, identified by abdominal ultrasonography, was significantly more prevalent in non-diabetic hypertensives (30.9%) compared to normotensive controls (12.7%). 29 The hypertensive group was also found to be insulin-resistant with higher levels of plasma insulin, confirming that essential hypertension forms part of the insulin resistance syndrome.
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The concern is that many hypertensive patients have unsuspected or undiagnosed fatty liver. Large population-based studies will be necessary to investigate the precise association of fatty liver with hypertension, and to determine the size of the problem.
There is an increasingly compelling relationship between liver dysfunction and the metabolic syndrome (Table 2) . [30] [31] [32] An abnormality in one liver function test is seen in up to 57% of unselected outpatients with diabetes. 33 Among male diabetics, the risk of NAFLD and hepatocellular carcinoma is double that of non-diabetics. 34 NAFLD also seems to explain the known association between diabetes and cryptogenic cirrhosis. 35 Hyperlipidaemia is also seen in 21-61% of patients with NAFLD, 36, 37 and conversely, 50% of hyperytriglyceridaemic patients have fatty liver. 38 Furthermore, up to 92% of patients with non-alcoholic steatohepatitis (NASH, the later stage of fatty liver disease) have hypertriglyceridaemia, with or without coexisting hypercholesterolaemia. 1 Obesity is the commonest association with NAFLD; 69-100% of patients with NASH are obese. 39 In 1515 patients with morbid obesity, only 12% of liver biopsies were found to be normal; 3% had cirrhosis and 80% fatty liver. 40 In a series of 551 liver biopsies performed on patients with severe obesity undergoing bariatric surgery, 86% had steatosis, 24% steatohepatitis and 2% cirrhosis. 41 The severity of fatty liver in obese patients positively correlates with body mass index (BMI). 42 Fatty Table 3 The relationship between GGT, obesity and hypertension 27 Baseline GGT (U/l) P for trend Figure 1 Complex interrelationship between the various components of the metabolic syndrome and NAFLD.
liver is particularly associated with abdominal fat distribution; this is independent of body weight. 43 This association was confirmed in type II diabetic men, where fatty liver scores significantly correlated with visceral/total adipose tissue ratio, serum triglycerides and insulin resistance. 44 Natural history of fatty liver NAFLD is increasingly recognized as a major cause of chronic liver disease and is characterized by macro-vesicular accumulation of fat in the hepatocytes (hepatic steatosis). 45 NAFLD is a spectrum from simple hepatic steatosis without inflammation, through steatohepatitis to cirrhosis (Figure 1 ). NASH is a chronic necro-inflammatory condition, which can lead to liver fibrosis and cirrhosis. 5, 8 The natural history of patients with NAFLD appears to be related to the stage of the disease. 46 Patients with simple steatosis have a more benign course, with 1.5% developing cirrhosis and 1% dying of liver disease over a 10-20-year period. 7, 46, 47 Patients with NASH, however, have a liver related mortality up to 11 and 20-25% of patients with NASH progressed to cirrhosis during 8-10 years follow-up. 48, 49 The risk of severe fibrosis in NASH was most pronounced in older patients, with obesity and diabetes. 9 Long-term survival in patients with NAFLD is comparable to that seen in patients with hepatitis C. 50 The presence of the features of the metabolic syndrome (diabetes, hypertension, obesity or hyperlipidaemia) in patients with NAFLD increases the severity of disease. 51 Cirrhosis resulting from NAFLD accounts for approximately 13% of all cases of hepatocellular carcinoma. 52 Unrelated to the risk of progressive liver disease in NAFLD, fatty liver can accelerate the progression of other forms of chronic liver disease, in particular hepatitis C.
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Pathogenesis of fatty liver
The pathogenesis of NAFLD remains poorly understood. A 'two-hit hypothesis' has been suggested, 55 in which the first insult to the liver (hit) induces hepatic steatosis, as a result of increased peripheral adipocyte lipolysis or increased hepatocyte triglyceride synthesis. However, progression to NASH and more severe liver disease is the result of a second 'hit'. It is unclear how the 'second hit' leads to the development of progressive liver disease, although oxidative stress and pro-inflammatory cytokines have been implicated. [56] [57] [58] The nature of these 'hits' is unknown.
Increasing attention is being given to the possible role of adiponectin as a regulator of liver injury in NAFLD. Adiponectin is a serum protein produced by adipoctyes and levels correlate inversely with BMI and hepatic fat content. 59 The effect of adiponectin is to block fatty acid synthesis, promote mitochondrial B-oxidation, 60 and inhibit the synthesis and release of TNF-a within adipose tissue. 61 Serum and hepatic adiponectin levels are lower in patients with NASH than in those with simple steatotsis. 56, 62 It has also been shown that exogenous adiponectin reverses experimental NAFLD and NASH, potentially via peroxisome proliferator-activated receptor-a (PPAR-a) . 63 This is supported by evidence that thiazolidinediones (which are PPAR-g agonists) stimulate adiponectin synthesis and are a potential therapeutic agent in fatty liver disease. 64 PPARs are an increasing focus of attention in the aetiopathogenesis of fatty liver. There are three PPARs, whose general effects are to promote fatty acid catabolism in non-adipose tissue and stimulate fatty acid storage in adipose tissue. 65 Animal models have also suggested a potential role for angiotensin II in the progression of NAFLD to hepatic fibrosis, 66 and the use of angiotensin II type 1 receptor antagonists has been shown to reduce this progression. 67 
Diagnosing fatty liver
NAFLD is asymptomatic in 45-100% of cases. 6, 68 The most common features are fatigue, malaise, abdominal discomfort and hepatomegaly. Most patients with NAFLD are initially identified as a result of an elevated serum alanine aminotransferase (ALT), often detected for the investigation of nonspecific symptoms, or detected during routine follow-up of other chronic diseases (e.g. diabetes or hypertension). Laboratory-based tests can neither confirm the diagnosis of fatty liver, nor can they distinguish between simple steatosis, NASH and cirrhosis. The most common abnormalities are elevations in ALT and aspartate aminotransferase (AST). The ratio of serum AST to ALT can be helpful in distinguishing NAFLD from alcohol-induced fatty liver; o1 in NAFLD and usually 42 in alcohol-induced liver disease. 69 Serum alkaline phosphatase and g-glutamyl transferase are often normal or only mildly elevated. The gold standard for diagnosing fatty liver is liver biopsy, which allows accurate differentiation between simple steatosis, NASH and cirrhosis. However, given the invasive nature and risks associated with liver biopsy, and in absence of an established treatment (see below), it is controversial as to which patients should be biopsied. 70 Our view is that outside clinical trials, liver biopsy is only indicated if there is doubt as to the nature of the liver disorder and if the liver function test abnormalities are severe or have significantly deteriorated over time.
The most important feature that indicates that simple steatosis is no longer 'simple' is the development of fibrosis as a result of NASH. Currently, fibrosis can be assessed only by liver biopsy, but there is promising research into serum markers of fibrosis (e.g. serum platelet-derived growth factor-BB), which raises the prospect of accurate noninvasive diagnosis of hepatic fibrosis. 71 Advances in imaging techniques are improving non-invasive assessment of fatty liver, but accurate non-invasive diagnosis of fatty liver remains difficult. Current techniques cannot assess the degree of hepatic fibrosis or inflammation. Ultrasound is the preferred modality for qualitative assessment of fatty liver, although it does not correlate well with histological findings. 72, 73 Assessment of liver density by calibrated computerized tomography and localized proton magnetic resonance spectroscopy shows promise.
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Treatment of fatty liver
The main aim of treatment in NAFLD is either to prevent the development of fibrosis or to stabilize and regress existing fibrosis; however, current therapeutic agents have limited efficacy.
The initial therapeutic approach to obese patients with NAFLD should be weight reduction and increased physical activity. 76 Weight reduction and exercise significantly improve serum aminotransferases, BMI and histological inflammatory activity, but do not improve the fibrosis scores. 77 Further evidence for the benefit of weight loss is provided by the observation that 89% of morbidly obese patients with NASH, who had gastric bypass surgery, no longer had the histological criteria for NASH at repeat liver biopsy, after successful postoperative weight loss. 78 As with all chronic liver diseases, avoidance of alcohol is a wise precaution. It is self-evident that other features of the metabolic syndrome should be screened for and treated in patients with NAFLD. There is no evidence yet, however, that treating diabetes, hyperlipidaemia or hypertension improves the outcome of NAFLD.
Pharmacological intervention has been directed at treating insulin resistance. The biguanide, metformin, reduces hyperinsulinemia and improves hepatic insulin resistance. 79 It is beneficial in animal models of NASH, 79 but initial open-label studies in humans suggested only transient improvements in serum liver enzymes. 80 In two recent small randomized trials of non-diabetic patients with NAFLD, metformin treatment significantly improved serum aminotransferases compared to treatment with calorie and lipid restricted diets, 81 or vitamin E, 82 but in only one study did metformin significantly decrease liver fat, necro-inflammation and fibrosis. 82 Thiazolidinediones act by mimicking certain actions of insulin. Troglitazone normalized serum ALT and improved inflammatory activity on liver biopsy, 83 but it can cause hepatocellular damage and has since been withdrawn. 84 Rosiglitazone reduced serum aminotransferases in diabetic and nondiabetic patients with NASH. 85, 86 Non-diabetic patients, who had biopsy-proven NASH, were treated with pioglitazone for 48 weeks; in 72%, ALT normalized, and in two-thirds liver histology improved. 87 There are encouraging results showing improvements in serum aminotransferases in NAFLD treated in small open-label trials with anti-oxidant agents (vitamin E 88 or a-tocopherol) 89 and with gemfibrozil (a lipid-lowering fibric acid derivative). 90 In an open-label study of non-diabetic patients with NAFLD and hyperlipidaemia, those with hypertriglyceridaemia received omega-3-fatty acids, those with hypercholesterolaemia were given atorvastatin and those with mixed dyslipidaemia and obesity received orlistat. 91 All patients had significant reductions in lipids and serum aminotransferases, with a complete normalization of aminotransferases in the orlistat group. 91 Ursodeoxycholic acid (URSO), which has anti-apoptotic and immunomodulatory effects, 92 improved serum ALT in a small open-label study, 93 but had no effect on ALT or liver histology in a larger randomized control trial. 94 There is a little evidence that anti-hypertensive therapy can directly benefit NAFLD. Losartan treatment of eight hypertensive patients with NASH led to a significant reduction in systemic arterial blood pressure, serum aminotransferases and markers of hepatic fibrosis. There was evidence of reduced necro-inflammation and fibrosis in some patients but no decrease in steatosis. 67 In contrast, some antihypertensives (b-blockers and thiazides) may lead to increased insulin resistance, so perhaps should be avoided in fatty liver disease. Moreover, some antihypertensives (e.g. b-blockers) may cause hepatotoxicity. 95, 96 Although there is some encouragement from the results of some open-label or small-scale drug trials, there is an absence of data from large randomized controlled trials. From this, we should conclude that no drug treatment is of proven benefit and as such it is premature to treat patients with fatty liver with any of these drugs. A management plan for NAFLD is suggested in Table 4 . 
Conclusion
The interaction of hypertension, fatty liver and the metabolic syndrome is complex. The clinical significance of fatty liver remains poorly understood, although there is clear evidence of potential progression to NASH, hepatic fibrosis and cirrhosis in high-risk groups. The treatment and management of patients with NAFLD is still poorly defined and as yet no therapeutic agents are of proven benefit. Despite this, the effective treatment of the associated conditions (diabetes, hyperlipidaemia and hypertension) will certainly confer cardiovascular benefit on these patients.
It is important to consider the diagnosis of fatty liver in hypertensive patients early, to measure the liver function tests at diagnosis and not to ignore minor elevations of serum aminotransferases.
Patients with raised liver enzymes should be referred to a gastroenterologist or hepatologist, especially those with risk factors for progressive NAFLD, such as obesity, diabetes and insulin resistance.
